A20-28z CAR T-cells

A20-28z CAR T-cells are an experimental second-generation chimeric antigen receptor (CAR) T-cell therapy designed to target the integrin αvβ6, a protein that is highly overexpressed in several aggressive solid tumors, including pancreatic ductal adenocarcinoma (PDAC), ovarian cancer, and breast cancer, while remaining largely absent in healthy adult tissues. The CAR construct is unique in its use of a 20-amino acid peptide (A20FMDV2) derived from the foot-and-mouth disease virus as the antigen-binding domain, rather than a traditional single-chain variable fragment (scFv). This binding domain is linked to a CD28 costimulatory domain and a CD3ζ signaling endodomain. To improve the ability of these cells to infiltrate solid tumors, researchers have further modified them to co-express the chemokine receptor CXCR2, which enhances homing toward interleukin-8 (IL-8) produced within the tumor microenvironment. Preclinical studies have demonstrated that these engineered T-cells exhibit potent cytolytic activity and improved therapeutic efficacy in xenograft models of pancreatic and ovarian cancer.

Other names

αvβ6-specific CAR T-cellsA20FMDV2-targeted CAR T-cellsA-20FMDV2-targeted CAR T-cellsA 20FMDV2-targeted CAR T-cellsA20-28z CXCR2 CAR T-cellsA-20-28z CXCR2 CAR T-cellsA 20-28z CXCR2 CAR T-cells